Vimarsana
Biggest News Aggregation in the World

Page 18 - Biontech Se News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biontech Se. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biontech Se Today - Breaking & Trending Today

Investegate |BioNTech SE Announcements | BioNTech SE: BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors - Vimarsana News

Investegate |BioNTech SE Announcements | BioNTech SE: BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

Investegate announcements from BioNTech SE, BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

BioNTech and DualityBio Form Global Strategic Partnership - Vimarsana News

BioNTech and DualityBio Form Global Strategic Partnership

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets...

Analysts' Price Target Changes for March 28th (1COV, ADS, AT1, BAS, BNTX, DGE, EVT, GLJ, IFXA, KGX) - Vimarsana News

Analysts' Price Target Changes for March 28th (1COV, ADS, AT1, BAS, BNTX, DGE, EVT, GLJ, IFXA, KGX)

Analysts’ price target changes for Tuesday, March 28th: Covestro (ETR:1COV) was given a €46.00 ($49.46) price target by analysts at Deutsche Bank Aktiengesellschaft. adidas (FRA:ADS) was given a €170.00 ($182.80) price target by analysts at Deutsche Bank Aktiengesellschaft. Aroundtown (ETR:AT1) was given a €2.60 ($2.80) price target by analysts at Warburg Research. Basf (ETR:BAS) was […]

BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook. - Vimarsana News

BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.

The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.

BioNTech shares slip on gloomy Covid vaccine sales outlook - Vimarsana News

BioNTech shares slip on gloomy Covid vaccine sales outlook

The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.

Source: cnbc.com